现货型病毒特异性T细胞治疗异基因造血干细胞移植后BK病毒、人疱疹病毒6型、巨细胞病毒、EB病毒及腺病毒感染
该II期临床试验在38例异基因造血干细胞移植后合并45次感染的患者中,输注识别EBV、AdV、CMV、BKV和HHV-6五种病毒的第三方供者来源VSTs。单次输注总体完全或部分缓解率为92%(95%CI 78.1%-98.3%),各病毒缓解率分别为BKV 100%(n=16)、CMV 94%(n=17)、AdV 71%(n=7)、EBV 100%(n=2)、HHV-6 67%(n=3)。输注安全,仅观察到2例新发1级移植物抗宿主病。
要点
- 单次输注现货型VSTs总体缓解率92%(95%CI 78.1%-98.3%),BKV感染缓解率100%(n=16)。
- 14例BKV相关出血性膀胱炎患者中13例在第6周前肉眼血尿完全消退。
- 输注安全,仅观察到2例新发1级移植物抗宿主病。
核心结论
- 使用库存VSTs是治疗异基因造血干细胞移植后严重且药物难治性感染的可行、安全且有效的方法,包括既往从未有现货型产品靶向的两种病毒(BKV和HHV-6)感染。
- VSTs的多特异性确保广泛的抗病毒覆盖,便于治疗合并多种感染的患者。
研究设计与样本
- II期临床试验,生成识别EBV、AdV、CMV、BKV和HHV-6五种常见病毒病原体的VSTs库。
- VSTs输注给38例异基因造血干细胞移植后合并45次感染的患者。
主要发现
- 单次输注总体完全或部分缓解率为92%(95%CI 78.1%-98.3%)。
- 各病毒缓解率:BKV 100%(n=16)、CMV 94%(n=17)、AdV 71%(n=7)、EBV 100%(n=2)、HHV-6 67%(n=3)。
- 31例治疗一种感染的患者和7例治疗多种同时感染的患者获得临床获益。
- 14例BKV相关出血性膀胱炎患者中13例在第6周前肉眼血尿完全消退。
- 输注安全,仅观察到2例新发1级移植物抗宿主病;通过表位分析追踪VSTs显示第三方来源功能性VSTs持续存在长达12周。
关键数值与推荐
- 总体缓解率92%(95%CI 78.1%-98.3%)。
- BKV感染缓解率100%(n=16);CMV 94%(n=17);AdV 71%(n=7);EBV 100%(n=2);HHV-6 67%(n=3)。
- 14例BKV相关出血性膀胱炎患者中13例在第6周前肉眼血尿完全消退。
- 仅观察到2例新发1级移植物抗宿主病。
- 第三方来源功能性VSTs持续存在长达12周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Improvement of cure rates for patients treated with allogeneic hematopoietic stem-cell transplantation (HSCT) will require efforts to decrease treatment-related mortality from severe viral infections. Adoptively transferred virus-specific T cells (VSTs) generated from eligible, third-party donors could provide broad antiviral protection to recipients of HSCT as an immediately available off-the-shelf product. Patient and Methods We generated a bank of VSTs that recognized five common viral pathogens: Epstein-Barr virus (EBV), adenovirus (AdV), cytomegalovirus (CMV), BK virus (BKV), and human herpesvirus 6 (HHV-6). The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. Results A single infusion produced a cumulative complete or partial response rate of 92% (95% CI, 78.1% to 98.3%) overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (n = 3). Clinical benefit was achieved in 31 patients treated for one infection and in seven patients treated for multiple coincident infections. Thirteen of 14 patients treated for BKV-associated hemorrhagic cystitis experienced complete resolution of gross hematuria by week 6. Infusions were safe, and only two occurrences of de novo graft-versus host disease (grade 1) were observed. VST tracking by epitope profiling revealed persistence of functional VSTs of third-party origin for up to 12 weeks. Conclusion The use of banked VSTs is a feasible, safe, and effective approach to treat severe and drug-refractory infections after HSCT, including infections from two viruses (BKV and HHV-6) that had never been targeted previously with an off-the-shelf product. Furthermore, the multispecificity of the VSTs ensures extensive antiviral coverage, which facilitates the treatment of patients with multiple infections.
引用
- Tzannou I, Papadopoulou A, Naik S, et al. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017. PMID: 28783452. doi:10.1200/JCO.2017.73.0655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。